Shared on04 Aug 25Fair value Decreased 8.41%
Despite improved profitability reflected in a higher net profit margin, CONMED’s valuation has compressed with a lower future P/E, leading analysts to reduce their consensus price target from $66.60 to $61.00. What's in the News CONMED Corporation raised its full-year 2025 revenue guidance to a range of $1.356 billion to $1.378 billion.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 0.59%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 15%
AnalystConsensusTarget has decreased revenue growth from 5.9% to 5.3%, decreased profit margin from 12.0% to 10.5% and increased future PE multiple from 15.7x to 18.7x.